Abcam, ab283698, Alexa Fluor® 488 Anti-HHLA2 antibody [EPR23563-120]

Size: 100µL
Rabbit Recombinant Monoclonal HHLA2 antibody - conjugated to Alexa Fluor® 488. Suitable for Flow Cyt and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23563-120,
Isotype:IgG,
Conjugation:Alexa Fluor® 488,
Excitation/Emission:Ex: 495nm, Em: 519nm,
Carrier free:No,
Reacts with:Human,
Applications:Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The HHLA2 protein also known as Human endogenous retrovirus-H Long Terminal Repeat-Associating 2 plays a role in the immune response. This protein is part of the B7 family which are known for their involvement in immunomodulation. It has a molecular weight of approximately 30 kDa. HHLA2 is expressed in various tissues including the placenta kidneys intestines and lungs. Additionally HHLA2 is typically upregulated in some cancer tissues which suggests a potential role in tumor immunity.
Biological function summary
HHLA2 acts as a co-inhibitory molecule that modulates T cell activity functioning to suppress T cell proliferation and cytokine production. It engages in the immune checkpoint pathways which are critical for maintaining immune tolerance and preventing over-activation of the immune system. HHLA2 does not act alone but rather interacts with other B7 family proteins in these pathways. It influences CTLA-4 and PD-1 mediated pathways by modulating the immune checkpoints adjusting the immune response based on physiological needs.
Pathways
HHLA2 fits into the immune checkpoint regulation pathways. It is known to modulate the PD-1/PD-L1 pathway which is essential for T cell immune evasion in cancer cells. Through its interactions HHLA2 can impact the tumor microenvironment by influencing immune cell infiltration and activation which is a significant aspect of cancer progression and immune evasion strategies. It is also related to CTLA-4 regulatory pathways which play an important role in maintaining immune homeostasis by negatively regulating T cell activation.
HHLA2 associates with cancer particularly certain solid tumors where its expression is increased suggesting its role in immune evasion. This association points to its potential as a therapeutic target for immunotherapy. HHLA2 is connected to proteins like PD-L1 and CTLA-4 which are already known targets in cancer therapy because of their roles in bypassing immune detection by tumors. Additionally its expression is linked to autoimmune diseases where dysregulation of immune checkpoints results in excessive immune cell activity against self-tissues.